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Abstract 
Debate continues as to whether executive function (EF), develop normally in children 
with PKU.  Using a mixed model, we measured EF in ten adolescent children with 
PKU and six sibling controls, and examined associations between cognitive function 
and phenylalanine (phe) as well as the phenylalanine:tyrosine ratio (phe:tyr).  
Measurements were taken on two occasions anticipated to yield variation in 
concurrent phe resulting from changes in dietary compliance (i.e. Christmas holiday 
versus non-holiday period).  A repeated measures ANOVA using Behaviour Rating 
Inventory of Executive Function (BRIEF) scores yielded the following results: no 
significant interactions; two significant group effects of substantially impaired 
working memory and initiation skills in children with PKU than controls irrespective 
of occasion; and, two significant time effects, suggestive of slightly poorer “non-
holiday” planning and organisation scores in both PKU and control groups.  Further 
analyses revealed that phe levels were not significantly different at the time occasions 
we sampled, suggesting that holiday dietary compliance may be better than expected.  
Correlations between EF and biochemistry in children with PKU showed that the 
participant’s phe:tyr ratio across their lifetime and particularly prior to age 12 years, 
demonstrated the greatest number of significant and strong positive correlations 
across most scales of EF impairment.   
 
KEYWORDS:  Phenylketonuria; Executive Function; Phenylalanine:Tyrosine Ratio; 
Adolescents; Dietary Compliance; BRIEF
Executive function in ECT-PKU 
3 
Biochemical markers associated with executive function in children with early and 
continuously treated Phenylketonuria (ECT-PKU): a preliminary study 
Approximately 1 in 14,500 live births in Australia will be diagnosed with 
phenylketonuria (PKU; 1) an inborn error of metabolism detected in Australia by 
newborn screening.  Elsewhere the incidence of PKU in Caucasian populations of 
European descent has been reported as approximately 1 in 10,000 (2).  PKU is of 
particular interest because of its potential to contribute to our understanding of the 
development of frontal lobe function, and continuing debate regarding the potential 
for “normal” cognitive development in affected individuals. 
PKU is a deficiency in the liver enzyme phenylalanine hydroxlase; which 
results in very high levels of the amino acid phenylanine (phe) and low levels of 
tyrosine.  Phe is toxic to the developing brain, resulting in major neurological damage, 
particularly to white matter tracts that develop post-natally.  Low tyrosine is 
hypothesised to lead to low dopamine production (as tyrosine is a precursor to 
dopamine).  The introduction of newborn screening for PKU has enabled earlier 
detection and treatment (phe restricted diet) which has lead to dramatic improvements 
in the neuropsychological function of people with PKU.  Specifically, the severe and 
inevitable intellectual impairment that developed as a consequence of untreated PKU 
(3) no longer occurs in early and continuously treated (ECT) PKU.  Research since 
has focused on whether, and to what extent, cognitive function remains impaired in 
individuals with this disorder (4, 5).  Current evidence suggests that children with 
ECT-PKU can achieve at least average IQs, although these scores may be slightly 
lower than those of their siblings and parents (5,6).  However, it has been suggested 
that higher level cognitive skills, particularly executive functions, might be impaired 
in children with ECT-PKU (5,7) with deficits persisting into adulthood (8). 
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Executive functioning (EF) describes abilities in goal directed behaviour, 
inhibition of automatic responses, self-regulation, task-switching, integration of 
information across space and time and working memory.  Deficits in executive 
function in children with ECT-PKU are more likely than in controls (5,7), in 
particular deficits in working memory (9; 10) and processing speed (10,11).   These 
residual EF deficits lead to a prevalence rate of attention deficit disorder five times the 
norm in children with ECT-PKU (12). 
The mechanism hypothesised to underlie executive function deficits in 
children with ECT-PKU remains largely biochemical, in that greater phe exposure 
leads to compromised executive function (9,10,13).  However, two studies have 
identified that the ratio of blood phe to tyrosine (phe:tyr ratio) has been shown to be a 
potentially more influential determinant of EF outcomes rather than phe-only 
measures (9, 14).   
The phe:tyr ratio effect on EF is due to a hypothesised link to dopamine levels, 
such that a higher phe:tyr ratio may lead to a lower dopamine environment for the 
developing brain, compared to high phe alone.  Phenylalanine and tyrosine are both 
large neutral amino acids and share the same transporter mechanisms to cross the 
blood brain barrier. Very high phe inhibits tyrosine transport into the brain so less is 
available for dopamine formation. Increased plasma levels of tyrosine may not 
improve this competition for transport if phenylalanine is also increased. A low 
phe:tyr ratio occurs when the plasma concentration of tyrosine is high relative to 
phenylalanine.  Despite findings that the phe:tyr ratio may be an important 
determinant of function, the impact of increasing dietary tyrosine to improve the ratio, 
and therefore EF, has not been widely investigated and findings so far have been 
inconsistent (15,16). 
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There remains a need for further studies of EF deficits among children with 
ECT-PKU (4), particularly those utilising longitudinal rather than cross-sectional 
designs (8) and with ecologically valid executive function tests (17 – 19).  There are 
also differences in the way studies operationalise “phe exposure”.  The majority of 
studies have used phe recorded at the time of neuropsychological testing variously 
referred to as “concurrent” phe (20) or “current” phe (8).  However, it may be also 
important to study “recent” phe exposure (i.e. an accumulation over the previous 
weeks or months) since short term phe fluctuations have been shown to affect 
cognition (21). Studies of the effects of lifetime phe exposure, also referred to as 
“historical” phe, have also been reported (8,20) and these studies also show strong 
relationships with cognitive variables. 
The possibility that the PKU cognitive profile might be partly underpinned by 
structural defects such as hypomyelination has also been suggested (20, 22).  
Evidence for abnormalities of this type comes from animal studies (23), as well as 
human imaging (8, 20, 24) and histomorphological dissection studies (25).  Review 
studies suggest that the neuroanatomical structures susceptible to developmental 
defects in PKU include those white matter tracts that develop post-natally, such as 
those of the corpus callosum and subcortical white matter (22).  More recent imaging 
studies have implicated areas such as the cerebrum and hippocampus (26).  Consistent 
associations between neuroanomatical anomalies and metabolic parameters have  
been difficult to demonstrate (20, 26, 27), and there is debate as to their possible 
reversibility (28).  Interestingly, where neuroanatomical abnormalities in people with 
PKU have been identified, the structures affected typically include those implicated in 
mediating deficits seen on neuropsychological examination and may provide another 
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explanation for poor performance that is independent of, or acts in conjunction with, 
effects due to neurochemical dysfunction. 
Given the ongoing debate regarding the exact nature and severity of EF 
deficits in ECT-PKU children, and a continuing need to better understand the 
biochemical factors that might contribute to such deficits, the aim of this study was to 
examine executive function in ECT-PKU children across two different time periods 
(holiday versus non-holiday) intended to capture fluctuations in concurrent phe.   Our 
hypothesis predicted that the stringent phe-restricted diet would be more difficult to 
maintain during the Christmas holiday period; which would in turn lead to higher 
concurrent phe and subsequent deterioration in EF.  A further purpose of this study 
was to determine which metabolic indicators including phe and tyrosine based indices 
were associated with EF in children with ECT-PKU. 
Method 
Participants 
The families of twenty-nine children with a diagnosis of ECT-PKU between 
the ages of eight and 17 years were mailed a study kit, comprising study details and 
questionnaires, via the Royal Children’s Hospital, Brisbane, Queensland, Australia.  
PKU diagnosis was based on plasma phenylalanine > 800 mmol/L at newborn 
screening.  Participants were also found to have: a) commenced treatment 
immediately after diagnosis; b) continued treatment up until the time of data 
collection (i.e. no discontinuation of diet/supplementation) and; c) undertaken regular 
(approximately monthly) blood checks.  Participants were also required by the 
administration of another psychological test instrument (results not reported in this 
paper) to have a minimum reading age of eight years.  Therefore, this sample is likely 
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to be positively skewed in terms of functional IQ as no severely affected participants 
were included.  
Parents were asked to select a sibling between eight and 17 years of age and 
closest in age to the child with PKU as a control subject.  The purpose of including a 
sibling group in this study was primarily to provide a control for score variation that 
might occur over time as a result of family and/or environmental effects associated 
with Christmas holiday versus non-holiday behaviours. 
Thirteen families with children with ECT-PKU responded, and eight of those 
families provided data for a non ECT-PKU child (sibling control); however, data from 
one sibling control was excluded from analysis due to failure to comply with study 
instructions; and data from one ECT-PKU participant was rejected because this 
participant was suspected of having an exceptional form of PKU1.  With these 
exclusions, the “Christmas holiday” sample comprised 12 children with ECT-PKU 
and 7 sibling controls.  Children in the ECT-PKU group were slightly older (age M = 
14.4 years, SD = 2.08) than sibling controls (age M = 13.1 years; SD =2.57, although 
this difference was not significant, t(17) = 1.18, p = .253. The ratio of males to 
females was higher in the ECT-PKU group (3:1) than sibling controls (approximately 
1:1). 
Given comorbid psychological diagnosis in children with ECT-PKU is not 
uncommon, we also collected a brief medical history.  No control sibling was 
identified by their parent as having a historical or current diagnosis of ADHD, autism 
                                                 
1 Data on this participant’s phe levels prior to age six years were missing; average phe level between 
six to 12 years of age was over double recommended Australian maximum at 735μmol/L; average phe 
after age 12 years over double recommended maximum at 1013 μmol/L, yet parents and treating 
metabolic physician reported normal cognitive function.  That is, this case had no known cognitive or 
neurological deficiencies in the context of relatively high phe exposure.  Koch et al., (2000) have 
recommended that such cases be regarded as “exceptional” (p. 1093), suggesting that they may 
represent an atypical form of PKU.  Given the focus of this study on classical PKU, this case was 
excluded from data analysis. 
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spectrum disorder (ASD), learning difficulty, depression or anxiety.  Compared to 
four (33%) of the children with ECT-PKU, who were identified by their parents as 
having a historical or current diagnosis of psychological/learning difficulties.  One of 
those four children was also identified as having ADHD and ASD and was on current 
medication (Ritalin). 
Three months later participants were approached for a second time and asked 
to complete the same measures.  Ten of the twelve eligible children with ECT-PKU 
and their siblings participated in this phase of the study, yielding one group of ten 
follow-up participants with ECT-PKU (8 males; age M = 14.4 years, SD = 2.16) and 
six sibling controls (4 male; age M = 14.0 years, SD = 2.21) respectively.  The 
treatment characteristics of ECT-PKU participants included in the final sample are 
shown in Table 1.  When compared to Australian treatment guidelines (29), the phe 
levels recorded for this group, reveal them to be a relatively adherent group, with the 
mean phe level for “under 12s” just over the recommended Australian maximum for 
this age group (i.e., <360 umol), and the mean phe level for “over 12’s” just under the 
upper limit for this age group (i.e., <500 umol).   
Insert Table 1 about here 
 
Materials 
Executive function 
Executive function was assessed by parent questionnaire – the Behaviour 
Rating Inventory of Executive Function (BRIEF; 30).  The BRIEF is a standardized 
clinical measure of children’s executive function designed to reflect the 
multidimensionality of this construct.  Since its publication in 2000, the BRIEF has 
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been used widely in research applications to assess executive function in children 
with: PKU (11), traumatic brain injury (31,32) ADHD and Tourette syndrome (33) 
and other acquired developmental disorders (34, 35).  
The BRIEF parent questionnaire contains 86 statements regarding the child’s 
behaviour.  Parents were instructed to rank each statement against instances of their 
child’s behaviour during the preceding “two weeks”, given this study’s focus on 
concurrent phe and recent instances of behaviour.  Statements are ranked on a “never, 
sometimes, often” basis and assess a wide range of executive functions reflected in 
eight “scales”: working memory, initiation, shifting, inhibition, planning and 
organisation, organisation of materials, emotional control and monitoring.  These 
scales contribute to three index scores: the Global Executive Composite (GEC), which 
is composite of each and every BRIEF scale score; the Behavioral Regulation Index 
(BRI), comprising emotional control, inhibit and shift scale scores; and the 
Metacognition Index (MI), which is a composite of initiate, working memory, 
planning/organisation, organisation of materials, and monitoring.  BRIEF scores have 
good internal consistency and test reliability (33) and the BRIEF provides an 
ecologically valid indication of EF of how the child actually functions in their 
environment on a day to day basis.   
T-scores were calculated to provide a clinically relevant measure of function, 
corrected for age and sex.  A T-score of 50 is considered average, with higher scores 
representing worse executive functioning; a T-score above 65 indicates clinical 
impairment.    
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Biochemistry 
Measures of concurrent phe and tyrosine as well as the phe:tyr ratio were 
collected for participants with ECT-PKU via guthrie card.  These scores were 
regarded as “concurrent” because participants were instructed to complete 
questionnaires on the same day they provided their blood sample for analysis.   
Lifetime phe exposure, lifetime tyrosine exposure, and the lifetime phe:tyr 
ratio were calculated by averaging the blood test results for each participant obtained 
from the regular blood tests from birth (excluding the original blood result used for 
diagnosis) to the end of 20052.  Finally, the average level of phe recorded for the year 
preceding data collection (i.e., 2005) was calculated for each ECT-PKU participant 
using archived laboratory records. 
Procedure 
Data were collected on two occasions chosen for their potential to yield 
different concurrent phe levels.  Participants were asked to complete the first set 
questionnaires in the first week of January 2006; a period selected because of its 
proximity to Christmas and New Year, thought to be associated with poorer dietary 
compliance and thus higher phe levels.  Participants were asked to complete the 
second set of questionnaires in March 2006, hypothesised to be a relatively benign 
period in terms of dietary compliance.   
 
 
 
                                                 
2 One participant had significant missing data (first six years of their life), having moved to Queensland 
from interstate, so was excluded from analyses regarding effects of “lifetime” levels.  This is because 
phe levels during infancy and early childhood are usually significantly lower than later years so any 
“lifetime average” levels calculated missing the first six years are likely to be substantially inflated. 
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Results 
The performance of ECT-PKU and control participants who completed 
executive function questionnaires on both occasions is shown in Table 2.  This table 
shows descriptive statistics for the eight BRIEF scale scores and BRIEF index scores.   
To test for statistically significant differences across time (holiday vs non-
holiday), between groups (control vs ECT-PKU), and as a product of time by group 
interactions, a series of repeated measures ANOVAs were run. For each analysis, the 
dependent measure was derived from the BRIEF (separate ANOVAs were run for 
each scale score and index).  There were two independent variables for each ANOVA.  
These were (a) time, a within groups factor with two levels (Christmas holiday and 
non-holiday) and (b) group, a between subjects factor with two levels (control versus 
ECT-PKU).  With alpha set at 0.05, four significant effects were observed (see Table 
2 for full ANOVA results, including group means and standard deviations).  Two of 
the four significant effects were time main effects suggesting deterioration over time 
in parents’ ratings of their children’s planning and organisational behaviour 
respectively, but this effect was clinically weak (in the order of three or four scale 
points, on average).  The third and fourth effects were a significant group effect on the 
BRIEF initiate and working memory scales (see Table 2).  On closer inspection, these 
group effects were due to worse reported performance by ECT-PKU participants than 
controls, irrespective of occasion. On average, ECT-PKU participants were separated 
from controls by more than one standard deviation on these scales (T score difference 
of 10 = 1 SD).  Finally, no significant group by time interactions were found, 
suggesting that the performance of ECT-PKU children was not differentially affected 
over time, compared to controls. 
Insert Table 2 about here 
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To further explore these findings, a series of exploratory analyses focused on 
the biochemical status of ECT-PKU children was conducted.  Given that we expected 
ECT-PKU children’s performance to be worse in January compared to March 
(because we assumed dietary compliance would be more difficult during holidays), 
we undertook a comparison of concurrent biochemical markers (phe, tyr, and phe:tyr 
ratio) over time.  Using a within subjects t-test to test for differences in concurrent phe 
between holiday and non-holiday periods, no significant differences were found, t(9) 
=  1.029, p = .331.  Further, when compared with historical measures, no significant 
differences between phe in 2005 and our two testing occasions were found.  Even 
when adjusted for age/different dietary restrictions (i.e. using historical phe levels 
after age 12 when a less restrictive diet is recommended in Australia), no significant 
differences were observed between historical phe (post 12 years of age only) and 
concurrent phe in January, t (7) = 1.886, p = .101, or March, t (7) = .819, p = .440.  
Suffice to say these analyses demonstrated that the concurrent phe levels collected for 
this study at both holiday and non-holiday periods appeared relatively consistent with 
historical phe levels during the preceding year and across the children’s lifetime. 
Concurrent biochemistry and executive function 
To explore the relationship between biochemical markers and performance on 
measures of executive function, a series of correlations were performed.  The results 
of correlational analyses revealed only two significant associations between 
concurrent biochemical markers and performance on the BRIEF scale and index 
scores.  Specifically, we found a significant correlation between concurrent phe at 
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time one3 and the BRIEF scales working memory, r (12) = .64, and planning, r (12) = 
.73 suggesting that higher concurrent phe levels were associated with worsening 
performance on these scales   
Correlational analyses using historical biochemical markers were also 
undertaken and significant results are shown in Table 3.  Notably, we found no 
significant correlations between our “recent” (averaged across 2005) measures of 
phe:tyr or tyrosine and executive function. 
Insert Table 3 about here 
 
Table 3 indicates the extent of significant positive correlations between 
executive function and the biochemical markers lifetime phe:tyr, phe:tyr prior to 12 
years, and to a lesser extent, lifetime phe, suggesting that longer exposure to 
biochemical markers underpin worsening executive function.  The overall pattern of 
results was similar regardless of whether time one or time two executive function 
scores were used.  The only significant association with lifetime tyr was a negative 
association with the EF scale of ‘organise’.  Importantly, working memory and initiate 
scores, the only scores identified as significantly different between ECT-PKU 
participants and controls in this study, were significantly and positively correlated 
with historical phe:tyr indices. 
Discussion 
Taking the significant time effects first, we found a modest increase in parent 
ratings of poorer non-holiday versus holiday EF in the scales of plan and organise 
across both groups (PKU and controls).  The result was clinically weak but achieved 
statistical significance due the power of the design (repeated measures) and because 
                                                 
3 The correlation between concurrent phe and these scales of the BRIEF at time two were not 
significant. 
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each and every parent rated their children’s EF on these scales as slightly worse 
during the school term.  A number of questions in the BRIEF relate to school 
performance, so it may be that parents unanimously rated their children’s performance 
as slightly worse during the school term due to recent instances of such behaviour, 
that were not evident during the Christmas holiday period. 
The primary purpose of this study was to explore differences in the executive 
function in children with ECT-PKU (a) across two different time periods (i.e., a 
comparison of performance measured at a period expected to be associated with poor 
dietary compliance and higher concurrent phe, with a period of usual dietary 
compliance/ lower concurrent phe), and; (b) compared to sibling controls.   
The predicted changes of elevated phe levels in the ECT- PKU group as a 
consequence of Christmas holiday occasion was not found.  This expectation was 
based on reports that adherence with PKU dietary guidelines can be more difficult for 
patients and their families during holiday/celebratory periods (36). The similarity of 
holiday and non-holiday phe levels, and their similarity to age-adjusted historical 
measures may suggest that improvements in dietary supplements (formulas) and in the 
availability of low phe foods and recipes or advances in patient education and 
counselling to support to dietary control (37) has made it easier for families with 
children with ECT-PKU to manage dietary restrictions at such times of year.   
The results of group comparisons of executive function in children with ECT-
PKU and sibling controls revealed that EF scales of initiate and working memory 
differed significantly between groups, with substantially worse function (more than 
one standard deviation apart on average) among children with ECT-PKU compared to 
controls on both occasions.  However, the group results are limited by a small sample 
size and underpowered analyses on all EF scales bar working memory.  It is possible 
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that impairment on other measures of EF would be demonstrated with a larger sample 
size (e.g. note the large mean differences observed between controls and ECT-PKU 
on Plan and Metacognition Index).  Nonetheless, our results support the proposition 
that working memory in particular, continues to show the strongest and most robust 
impairment in children with ECT-PKU, even within such a small sample.   
We explored the relationship between executive function and a broader range 
of biochemical markers than has been used previously.  The majority of past studies 
have focused on associations between behaviour/executive function and concurrent 
and/or historical phe only, and our inclusion of measurements of tyrosine, both 
concurrently and historically, extends previous research paradigms that have not 
explored the impact of tyrosine specifically.   
Overall our results provide relatively little support for the idea that concurrent 
biochemistry is strongly and consistently related to EF performance.  This finding is 
consistent with several previous reports (8, 20, 38, 39) but not others (9, 40-42).  This 
inconsistency may be a result of differences in EF measurement (ecologically valid 
tasks versus laboratory based measures), phe (mean or median phe levels or summary 
phe scores based on variable blood collection regimes), participant age and treatment 
history (compliant versus non-compliant samples assessed on or before possible 
critical periods for phe exposure, or a combination thereof  - see (43-45) for a fuller 
discussion of some of these issues).  Our analysis of concurrent versus recent versus 
lifetime biochemistry in this sample of adolescents demonstrated that phe levels were 
highly consistent across the lifespan.  This may explain why some studies that focus 
on concurrent phe only continue to show significant correlations, as in our sample 
concurrent phe was shown to be a good measure of lifetime phe, and this has been 
demonstrated by others (46, 47).   
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The most consistent pattern of associations we found was between EF and 
participant’s lifetime and < 12 years of age phe:tyr ratio.  The EF measures that 
proved most impaired between controls and children with ECT-PKU (Working 
Memory and Initiate) showed strong and significant correlations with historical 
phe:tyr measures.  Interestingly, recent (2005) and concurrent phe:tyr showed no 
relationship whatsoever with measures of EF, and given the strongest correlations 
were observed between phe:tyr below age 12 years and EF, this may indicate a 
potential sensitive period in brain development that needs further follow up.   
We identified one significant negative correlation between lifetime tyrosine 
and the Organise scale, suggesting that tyrosine on its own is not usually associated 
with performance on executive function tasks in children with ECT-PKU.  
Nonetheless our one significant negative correlation was in the direction predicted by 
the dopamine theory i.e. lower tyrosine = higher EF impairment.  The reason why 
tyrosine itself is neither strongly nor consistently related to executive function, but the 
phe:tyr ratio is, remains unclear.  Increased plasma levels of tyrosine may not improve 
the competition for transport if phenylalanine is also increased. A low phe:tyr ratio 
occurs when the plasma concentration of tyr is high relative to phenylalanine and this 
should allow more tyrosine to cross into the brain (48).   
Overall the results of this study add to the body of literature that suggests that 
specific aspects of executive function may be impaired relative to controls in children 
and adolescents with ECT-PKU, especially working memory.  In terms of 
contributing factors to EF impairment in children with ECT-PKU, the strongest 
association we found was between selected historical biochemical parameters 
(especially phe:tyr ratio) and performance, though future studies are needed to 
identify if and how these factors may be linked causally.  Although our sample was 
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small in terms of absolute numbers of participants, the effect sizes observed and 
strength of association with biochemical markers were generally robust.  In addition, 
the results of this study, by accounting for a broader range of historical biochemical 
parameters than has been studied previously, has strongly suggested that phe:tyr data 
should be taken into consideration in the design of future studies.  
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Table 1.   
Treatment Variables and Phe Exposure (in µmols) of ECT-PKU Participants. 
Phe levels N % of sample within 
recommended 
guidelines 
M SD min Max 
Continuity of treatment / Frequency of 
blood test (weeks):               
prior to age 12 
after age 12
 
 
10 
 
 
- 
 
 
4.5 
5.8 
 
 
- 
 
 
2.3 
3.3 
 
 
8.0 
9.6 
Concurrent phe (January, 2006) 10 40 601.30 204.95 270.00 970.00 
Concurrent phe (March, 2006) 10 70 478.00 274.26 210.00 1100.00 
Average phe aged < 12 years  10 70 383.00 96.91 267.00 580.00 
Average phe aged >12 years 8 62.5 491.75 127.83 367.00 742.00 
Lifetime phe  10 - 395.80 102.83 276.00 626.00 
Note: Phe levels and continuity of treatment data prior to, and after, age 12 are shown separately because allowable limits of phe change at this 
age, according to current Australian PKU management guidelines (ASIEM, 2005).  Continuity of treatment data was based on information 
current as of January 2006.  Standard deviations for “blood test frequency” were not available for this study.
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Table 2. 
Descriptive Statistics and Results of Repeated Measures Analysis of Variance for ECT-PKU (N = 10) and Sibling Control Participants 
(N = 6 using T-scores from the Behaviour Rating Inventory of Executive Function (BRIEF) at two time periods. 
BRIEF Score Group January March F test 
Scales     
Inhibit ECT-PKU 54.30 (14.38) 58.40 (17.59)  
Control 55.83 (8.54) 53.50 (8.36)  
Shift ECT-PKU 53.60 (13.41) 58.10 (14.82)  
Control 45.33 (6.28) 48.67 (12.16)  
Emotional ECT-PKU 56.40 (12.70) 57.3 (15.31)  
Control 58.17 (6.99) 57.67 (11.72)  
Initiate ECT-PKU 63.40 (11.25) 62.50 (11.07)  
Control 49.33 (9.31) 53.67 (12.40) Sig. group effect: F = 5.099; p = .04; partial eta2 = .267; η2  = .557 
Work Mem ECT-PKU 63.50 (10.42) 64.30 (12.22)  
Control 48.50 (8.90) 50.17 (12.73) Sig. group effect: F= 6.790; p = .021; partial eta2 = .327; η2  = .679 
Planning ECT-PKU 60.10 (11.34) 64.00 (11.12)  
Control 48.67 (10.30) 53.17 (10.57) Sig. time effect: F = 6.517; p = .023; partial eta2 = .318; η2 = .661 
Organise ECT-PKU 54.30 (9.75) 59.20 (8.15)  
Control 52.50 (13.01) 55.67 (12.92) Sig. time effect F = 5.116; p = .04; partial eta2 = .268; η2  = .558 
Monitoring ECT-PKU 56.70 (8.74) 61.30 (9.53)  
 Control 52.67 (6.68) 52.83 (9.62)  
Indexes     
BRI ECT-PKU 55.80 (14.42) 58.30 (17.72)  
Control 54.17 (7.86) 54.33 (10.29)  
MI ECT-PKU 61.20 (9.95) 63.90 (10.42)  
Control 50.17 (10.18) 53.00 (12.74)  
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GEC ECT-PKU 60.30 (11.28) 63.10 (13.24)  
 Control 51.83 (12.59) 53.83 (12.59)  
Note: Higher T-scores on BRIEF scales indicate worse performance; GEC = Global Executive Composite (GEC) of each and every BRIEF 
scale; BRI (Behavioral Regulation Index) is a composite score comprising emotional control, inhibit and shift; Metacognition Index (MI) is a 
composite score of initiate, WM, Plan/org., org materials, and monitor. η2  is observed power. 
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Table 3 
Significant Correlations Between Historical Biochemistry (Average Phe In 2005, Lifetime Phe, Lifetime Tyr, Lifetime Phe:Tyr and 
Phe:Tyr prior to age 12) and Executive Function (Behavioual Rating Inventory of Executive Function Scale and IndexT- Scores) at Two Time 
Periods in 10 adolescents with ECT-PKU. 
 Ave phe in 2005 Lifetime phe Lifetime tyr Lifetime phe:tyr Phe:tyr prior to 12 
BRIEF January March January March January March  January  March  January March 
Scales            
Inhibit .671* .752* .737** .883** - - - - - .655* 
Shift .713** .80** - .793** - - .636* .804** .763** .820** 
Emotion .691* .857* - .782** - - .673* .882** .796** .914** 
Initiate - - - - - - - .796** .668* .841** 
WM - .693* - - - - .668* .841** .695* .813** 
Plan -  - - - - - -  .689* .682* .638* 
Organise - - - - -.654* - -  - - 
Monitor - .760* - .662* - - - .803** .604* .781** 
Indexes           
BRI  .743** .819** .651* .796** - - .671* .835** .763** .863** 
MI - - -  - -  .813** .709** .786** 
GEC .647* .763* - .648* - - .675* .887** .786** .879** 
Note:  
* = p <.05; ** = p < 0.01. 
 
